Table 1.
Results.
| Patient characteristics | All patients (n = 200) | Patients with intestinal parasites (n = 18) | Patients without intestinal parasites (n = 182) | P value |
|---|---|---|---|---|
| Gender male, n (%) | 136 (68%) | 17 (94.4%) | 119 (65.4%) | 0.012 |
| WHO staging of HIV, n (%) | 0.076 | |||
| Stage 1 | 11 (5.5%) | 0 (0%) | 11 (6%) | |
| Stage 2 | 34 (17%) | 2 (11%) | 32 (17.6%) | |
| Stage 3 | 145 (72.5%) | 13 (72.2%) | 132 (72.5%) | |
| Stage 4 | 10 (5%) | 3 (16.7%) | 7 (3%) | |
| Diarrhoea, n (%) | 91 (45.5%) | 15 (83.3%) | 76 (41.8%) | 0.001 |
| Immune status, n (%) | 0.000 | |||
| No immunosuppression (CD4 > 500 cells/µL) | 76 (38%) | 1 (5.6%) | 75 (41.2%) | |
| Mild immunosuppression (CD4 350–499 cells/µL) | 40 (20%) | 3 (16.7%) | 37 (20.3%) | |
| Advanced immunosuppression (CD4 200–349 cells/µL) | 34 (17%) | 2 (11.1%) | 32 (17.6%) | |
| Severe immunosuppression (CD4 < 200 cells/µL) | 50 (25%) | 12 (66.7%) | 38 (20.9%) | |
| HAART, n (%) | 147 (73.5%) | 13 (72.2%) | 134 (73.6%) | 0.898 |
| Cotrimoxazole prophylaxis, n (%) | 57 (28.5%) | 5 (27.8%) | 52 (28.6%) | 0.943 |
| Drinking water, n (%) | 0.004 | |||
| Boiled water | 87 (43.5%) | 2 (11.1%) | 85 (46.7%) | |
| Tap water | 113 (56.5%) | 16 (88.9%) | 97 (53.3%) |
WHO, World Health Organisation; HAART, highly active antiretroviral therapy.